메뉴 건너뛰기
Acta Urologica Japonica
Volumn 55, Issue 4, 2009, Pages 209-214
Assessment of recommended dose of dutasteride on Japanese men with benign prostatic hyperplasia: A randomized, double-blind, placebo-controlled, parallel-group, dose response study
Author keywords

5 alpha reductase inhibitor; Benign prostatic hyperplasia; Dutasteride; Japanese.
Indexed keywords

AZASTEROID; DUTASTERIDE; ENZYME INHIBITOR;
EID: 66249095157     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (8)
References (9)
  • 1
    • 0031134477 scopus 로고    scopus 로고
    • Epidemiology and natural history of benign prostatic hyperplasia
    • Tsukamoto T and Masumori N : Epidemiology and natural history of benign prostatic hyperplasia. Int J Urol 4 : 233-246, 1997
    • (1997) Int J Urol , vol.4 , pp. 233-246
    • Tsukamoto, T.1    Masumori, N.2
  • 2
    • 66249097160 scopus 로고    scopus 로고
    • Japanese source
  • 3
    • 66249119800 scopus 로고    scopus 로고
    • Japanese source
  • 4
    • 0030886845 scopus 로고    scopus 로고
    • Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR
    • Bramson HN, Hermann D, Batchelor KW, et al.: Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther 282 : 1496-1502, 1997
    • (1997) J Pharmacol Exp Ther , vol.282 , pp. 1496-1502
    • Bramson, H.N.1    Hermann, D.2    Batchelor, K.W.3
  • 5
    • 2442545242 scopus 로고    scopus 로고
    • Marked suppression of dihydrotestosteronc in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor
    • Clark RV, Hermann DJ, Cunningham GR, et al.: Marked suppression of dihydrotestosteronc in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 89 : 2179-2184, 2004
    • (2004) J Clin Endocrinol Metab , vol.89 , pp. 2179-2184
    • Clark, R.V.1    Hermann, D.J.2    Cunningham, G.R.3
  • 6
    • 0036754256 scopus 로고    scopus 로고
    • Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    • Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 : 434-441, 2002
    • (2002) Urology , vol.60 , pp. 434-441
    • Roehrborn, C.G.1    Boyle, P.2    Nickel, J.C.3
  • 7
    • 4444336295 scopus 로고    scopus 로고
    • Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia
    • Debruyne F, Barkin J, van Erps P, et al.: Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46 : 488-495, 2004
    • (2004) Eur Urol , vol.46 , pp. 488-495
    • Debruyne, F.1    Barkin, J.2    Van Erps, P.3
  • 8
    • 1842688886 scopus 로고    scopus 로고
    • Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia
    • Roehrborn CG, Marks LS, Fenter T, et al.: Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 63 : 709-715, 2004
    • (2004) Urology , vol.63 , pp. 709-715
    • Roehrborn, C.G.1    Marks, L.S.2    Fenter, T.3
  • 9
    • 0038311875 scopus 로고    scopus 로고
    • Safety and tolerability of the dual 5 a -reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia
    • Andriole GL and Kirby R : Safety and tolerability of the dual 5 a -reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 44 : 82-88, 2003
    • (2003) Eur Urol , vol.44 , pp. 82-88
    • Andriole, G.L.1    Kirby, R.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.